LeMaitre Vascular (NASDAQ:LMAT) Updates Q1 2025 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) updated its first quarter 2025 earnings guidance on Thursday. The company provided EPS guidance of 0.480-0.530 for the period, compared to the consensus EPS estimate of 0.510. The company issued revenue guidance of $56.7 million-$58.7 million, compared to the consensus revenue estimate of $58.1 million. LeMaitre Vascular also updated its FY 2025 guidance to 2.150-2.320 EPS.

Analysts Set New Price Targets

A number of brokerages have issued reports on LMAT. Lake Street Capital upped their target price on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a research report on Friday. Wells Fargo & Company began coverage on LeMaitre Vascular in a research report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 target price for the company. Oppenheimer cut LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday. Barrington Research lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday. Finally, StockNews.com lowered LeMaitre Vascular from a "buy" rating to a "hold" rating in a report on Friday, December 13th. Five investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $95.25.

Remove Ads

LeMaitre Vascular Price Performance

Shares of LMAT stock traded up $0.31 during trading hours on Monday, hitting $92.16. 299,488 shares of the company's stock were exchanged, compared to its average volume of 137,430. The stock's 50-day moving average is $96.89 and its 200-day moving average is $94.90. The stock has a market cap of $2.07 billion, a price-to-earnings ratio of 50.36, a price-to-earnings-growth ratio of 2.22 and a beta of 0.96. LeMaitre Vascular has a 52 week low of $62.39 and a 52 week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, hitting the consensus estimate of $0.49. The company had revenue of $55.81 million for the quarter, compared to analysts' expectations of $55.99 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. Equities research analysts forecast that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th will be issued a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 0.87%. The ex-dividend date is Thursday, March 13th. This is a boost from LeMaitre Vascular's previous quarterly dividend of $0.16. LeMaitre Vascular's dividend payout ratio is presently 41.24%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.